RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
13 EUR
-0.1 (-0.76%)
We assign a fundamental rating of 5 out of 10 to RHK. RHK was compared to 33 industry peers in the Health Care Providers & Services industry. RHK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RHK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RHK was profitable.
RHK had a positive operating cash flow in the past year.
In the past 5 years RHK has always been profitable.
RHK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RHK has a worse Return On Assets (2.02%) than 60.61% of its industry peers.
Looking at the Return On Equity, with a value of 2.90%, RHK is doing worse than 69.70% of the companies in the same industry.
The Return On Invested Capital of RHK (2.67%) is worse than 69.70% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RHK is below the industry average of 6.56%.
The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
RHK has a Profit Margin (2.28%) which is in line with its industry peers.
RHK's Profit Margin has declined in the last couple of years.
The Operating Margin of RHK (2.86%) is worse than 69.70% of its industry peers.
In the last couple of years the Operating Margin of RHK has declined.
The Gross Margin of RHK (66.81%) is better than 72.73% of its industry peers.
In the last couple of years the Gross Margin of RHK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
Compared to 1 year ago, RHK has about the same amount of shares outstanding.
The number of shares outstanding for RHK remains at a similar level compared to 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
RHK has an Altman-Z score of 3.09. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.09, RHK is doing good in the industry, outperforming 78.79% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
RHK has a better Debt to Equity ratio (0.09) than 93.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.09 |
ROIC/WACC0.41
WACC6.48%
2.3 Liquidity
RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RHK (2.28) is better than 93.94% of its industry peers.
A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
RHK has a better Quick ratio (2.19) than 93.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased strongly by -15.41% in the last year.
The Earnings Per Share has been growing slightly by 0.03% on average over the past years.
The Revenue has grown by 9.10% in the past year. This is quite good.
Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 4.12% on average per year.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.89% yearly.
RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.24% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.81, RHK is valued on the expensive side.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
The average S&P500 Price/Earnings ratio is at 26.61. RHK is around the same levels.
A Price/Forward Earnings ratio of 17.01 indicates a rather expensive valuation of RHK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of RHK to the average of the S&P500 Index (24.01), we can say RHK is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.81 | ||
| Fwd PE | 17.01 |
4.2 Price Multiples
96.97% of the companies in the same industry are more expensive than RHK, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.3
PEG (5Y)670.67
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
RHK has a yearly dividend return of 0.77%, which is pretty low.
Compared to an average industry Dividend Yield of 1.57, RHK has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.87, RHK's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (12/22/2025, 7:00:00 PM)
13
-0.1 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap870.48M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (11.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.43%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.81 | ||
| Fwd PE | 17.01 | ||
| P/S | 0.53 | ||
| P/FCF | N/A | ||
| P/OCF | 14.11 | ||
| P/B | 0.67 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | 0.51 |
EPS(TTM)0.57
EY4.38%
EPS(NY)0.76
Fwd EY5.88%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.09%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.3
PEG (5Y)670.67
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.09 |
F-Score6
WACC6.48%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y28.34%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.
What is the valuation status for RHK stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
What is the profitability of RHK stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.
What is the valuation of RHOEN-KLINIKUM AG based on its PE and PB ratios?
The Price/Earnings (PE) ratio for RHOEN-KLINIKUM AG (RHK.DE) is 22.81 and the Price/Book (PB) ratio is 0.67.
Can you provide the expected EPS growth for RHK stock?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 4.3% in the next year.